Immune-Modulating Peptide

Thymosin Alpha-1

Thymalfasin • 28-Amino-Acid Immune Peptide

Thymosin Alpha-1 is a naturally occurring immune-regulatory peptide studied for T-cell maturation, antiviral defense, vaccine response, immune restoration, inflammation balance, and adjunctive cancer care.

Immune Support Antiviral Research Vaccine Response Immune Modulation

Protocol Snapshot

Thymosin Alpha-1 Quick Reference

Verified Vendors

Thymosin Alpha-1

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Clinical Reference

1.6mg

Used twice weekly in multiple disease-specific trials.

Typical RUO Cycle

4–8 Weeks

Often followed by a 4-week break.

Frequency

Twice Weekly

Common published and community schedule.

Route

Subcutaneous Injection

Injection route used in published trials.

Peptide Grade

GradeB

Decades of international clinical use and human research across viral illness, vaccine response, sepsis, and oncology make thymosin alpha-1 unusually credible for this category, but results remain condition-specific and it still lacks FDA approval in the United States.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is Thymosin Alpha-1?

Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide produced from the precursor protein prothymosin alpha. The synthetic pharmaceutical form is called thymalfasin and is sold internationally under the brand name Zadaxin.

The thymus gland uses Thymosin Alpha-1 as an immune-regulatory signal that supports T-cell maturation, innate immune detection, dendritic-cell activity, natural killer cell function, cytokine balance, and antiviral defense.

Unlike compounds that simply stimulate immunity, Thymosin Alpha-1 is described as an immune modulator. It can enhance weak immune responses while also helping regulate excessive inflammatory signaling depending on the biological context.

Extensive Human Research

Thymosin Alpha-1 has decades of human research across chronic viral hepatitis, sepsis, vaccine response, and oncology-adjunct settings, with condition-specific and sometimes mixed outcomes.

Thymosin Alpha-1 Benefits

Immune Restoration

Supports T-cell maturation, CD4+ and CD8+ activity, dendritic cells, natural killer cells, and age-related immune decline.

Antiviral Support

Studied most extensively in chronic hepatitis B and C, with additional research in severe viral illness and post-viral immune dysfunction.

Vaccine Response

Clinical studies in older adults reported improved antibody responses and reduced influenza incidence when used alongside vaccination.

Cancer-Therapy Adjunct

Studied alongside conventional treatment to restore immune function and improve tumor-cell recognition, not as a replacement for oncology care.

Inflammatory Balance

Modulates cytokines including IL-2, interferon-gamma, IL-10, and TNF-alpha rather than simply pushing immunity upward.

Healthy Aging

May help counter immunosenescence, reduced thymic output, impaired vaccine response, and declining T-cell diversity with age.

Protocol Planning

Dosing, cycling, and preparation

Thymosin Alpha-1 Dosing Protocol

Clinical use depends on the condition being treated. Chronic infection, cancer adjunct therapy, transplant status, and autoimmune disease require physician supervision.

Common RUO Protocol

Dose

1.6mg per injection

Frequency

Twice weekly

Timing

Any time of day; no fasting required

Route

Subcutaneous injection

Cycle

4–8 weeks, often followed by 4 weeks off

Published Clinical Context

Chronic HBV

1.6mg twice weekly for 24 weeks

Vaccine Study

900mcg/m² twice weekly for 8 doses alongside influenza vaccination

HBV-ACLF Study

1.6mg daily for week 1, then twice weekly through week 12

Evidence Context

These were disease-specific, medically supervised research schedules

Dose Context Matters

Although 1.6mg twice weekly appears in multiple published studies, it is not a universally validated wellness dose. Clinical schedules vary by disease, combination therapy, and study design.

Thymosin Alpha-1 Reconstitution

Mixing Details

Vial Size

10mg

Diluent

2mL bacteriostatic water

Concentration

5mg/mL

Storage

Refrigerate after reconstitution

Reconstitution Calculator

Syringe Conversion

250mcg

5 units

500mcg

10 units

1mg

20 units

1.6mg

32 units

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Fewer seasonal infections and shorter recovery time from colds are the most consistent reports.
Some users with post-viral fatigue or chronic viral conditions report improved stamina and reduced symptom burden.
Users tracking bloodwork sometimes report increased white-cell, lymphocyte, or CD4 counts.
Benefits are often described as supportive rather than immediately noticeable.
Seasonal 4- to 8-week cycles are commonly used during cold and flu months.
Most users report minimal side effects.

Negative Reports

Some users report that perceived benefits fade after stopping.
Some users complete a cycle without noticing a meaningful change.
Transient fatigue, headache, insomnia, or injection-site irritation are occasionally reported.

Stacking & Synergy

Potential Thymosin Alpha-1 pairings and tracking context

Thymosin Alpha-1 Stacking & Synergy

TA-1 + Vilon — Strongest Immune Duo

Vilon provides broad immune and thymus support while TA-1 enhances T-cell function. A strong foundational immune stack.

TA-1 + BPC-157 — Immune + Healing

A practical pairing for gut-immune support or recovery from illness or injury.

TA-1 + KPV / KLOW

A community-used immune and inflammatory-support pairing, but controlled combination data is absent.

Checkpoint Inhibitors

Do not combine without oncology supervision because excessive immune activation is possible.

Free with login

Track in Journal

Compare TA-1 dosing with immune resilience, recovery, and tolerance.

Dose, timing, cycle day, and injection site.
Illness frequency, severity, and recovery.
Energy, sleep, inflammation, and autoimmune symptoms.
Vaccines, immune therapies, and medication changes.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

Thymosin Alpha-1 Side Effects

Human trials generally describe Thymosin Alpha-1 as well tolerated, but immune-active combinations can create important risks.

A severe multisystem adverse event has been reported when Thymosin Alpha-1 was combined with a PD-1 checkpoint inhibitor. Immune-therapy combinations require oncologist supervision.

In Published Research

Most trials reported mild injection-site reactions and a favorable overall safety profile.
Rare excessive immune activation may occur with checkpoint inhibitors or other strong immune therapies.
Long-term safety in healthy anti-aging use remains less established than disease-specific clinical use.

What Users Report

Common: redness, mild swelling, or tenderness at the injection site.
Uncommon: transient fatigue, mild headache, insomnia, nausea, or joint discomfort.
New rash, breathing difficulty, marked swelling, or systemic symptoms require medical evaluation.

Thymosin Alpha-1 Contraindications and Precautions

Do Not Use If You Have

An active organ transplant requiring immunosuppression.
Known hypersensitivity to Thymosin Alpha-1 or formulation ingredients.
Active checkpoint-inhibitor or cancer-immunotherapy treatment without oncologist approval.

Use Caution With

Autoimmune disease, especially when using TNF inhibitors or biologics.
Pregnancy, breastfeeding, or pediatric use because safety is not established.
Active cancer treatment, where use must remain coordinated with oncology care.

Drug Interactions

Checkpoint inhibitors, transplant immunosuppressants, and immune-suppressing biologics require particular caution. Thymosin Alpha-1 has been used clinically with interferon, ribavirin, vaccines, and selected chemotherapy regimens under supervision.

Monitoring

Depending on the indication, monitoring may include CBC with differential, lymphocyte subsets, liver tests, inflammatory markers, viral markers, vaccine response, and autoimmune symptoms.

Regulatory Status

Thymalfasin is used as an approved drug in multiple countries but is not FDA approved in the United States. FDA has cited potential immunogenicity and peptide-impurity concerns for compounded TA-1 and says available safety information is insufficient to define the extent of risk.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Thymosin Alpha-1 is one of the most reliable immune modulators in the peptide space.

The community respects it for good reason: it strengthens immune surveillance, helps clear chronic viral loads, speeds recovery from illness, and brings balance to an overactive or suppressed immune system. Users dealing with frequent infections, long COVID, mold exposure, or general immune senescence consistently report fewer sick days, better energy, and improved blood markers.

It may not be flashy, but it’s effective. In a world full of overhyped compounds, TA-1 delivers quiet, consistent results—especially when stacked with Vilon or used during travel/training blocks. It shines as a foundational immune support tool rather than a daily performance enhancer. If your immune system is the weak link holding back training consistency or longevity goals, TA-1 is one of the smartest additions you can make. Clean, well-tolerated, and backed by decades of real clinical use in multiple countries.

Highly recommended for anyone over 40 optimizing long-term health. Solid, no-nonsense peptide that should always be kept on hand in your peptide case. Better to have it and not need it than need it and not have it.